A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Active, not recruiting · Phase 2 · NCT02251548
Conditions: Chronic Lymphocytic Leukemia, Leukemia
At a glance
- Research payments reported, 2025
- $3.1M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 85
About the trial
- Sponsor
- Dana-Farber Cancer Institute (with Pharmacyclics LLC., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership)
- Tested
- Ibrutinib (drug), Fludarabine (drug), Cyclophosphamide (drug), Rituximab (drug)
- Dates
- Started 2014-10; completion 2027-01
- Results posted
- Yes
This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
From ClinicalTrials.gov, last updated 2026-07-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3.1M in research payments for this study in 2025 (11 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $3.1M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.